We are live on
!
Find out more
Mirae Asset Global Investments Portfolio holdings
AUM
$67.7B
1-Year Est. Return
57.61%
This Fund
S&P 500
This Quarter
Est. Return
+4.4%
1 Year Est. Return
+57.61%
3 Year Est. Return
+150.9%
5 Year Est. Return
+201.56%
10 Year Est. Return
+1,018.7%
AUM
$24.6B
AUM Growth
+$2.03B
(+9%)
Cap. Flow
+$1.28B
Cap. Flow
% of AUM
5.2%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
1,702
New
151
Increased
731
Reduced
674
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$167M |
| 2 |
Apple
AAPL
|
+$66M |
| 3 |
Microsoft
MSFT
|
+$57.3M |
| 4 |
HDFC Bank
HDB
|
+$44M |
| 5 |
Schwab US Dividend Equity ETF
SCHD
|
+$41.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$81.5M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$81.3M |
| 3 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$45.8M |
| 4 |
Advanced Micro Devices
AMD
|
+$43.4M |
| 5 |
Meta Platforms (Facebook)
META
|
+$35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.15% |
| 2 | Consumer Discretionary | 10.25% |
| 3 | Communication Services | 8.94% |
| 4 | Healthcare | 6.61% |
| 5 | Financials | 5.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Stoke Therapeutics
STOK
$2.02B
| $19.5K | ﹤0.01% |
+1,765
| New | +$21.7K |
|
1427
Oric Pharmaceuticals
ORIC
$1.42B
| $19.4K | ﹤0.01% |
2,352
-199
| -8% | -$1.83K |
|
1428
Futu Holdings
FUTU
$14.7B
| $19.2K | ﹤0.01% |
238
| – | – |
|
|
GOOD
1429
Gladstone Commercial Corp
GOOD
$641M
| $19K | ﹤0.01% |
1,187
-368
| -24% | -$6.09K |
|
|
MESO
1430
Mesoblast
MESO
$2.14B
| $18.7K | ﹤0.01% |
+1,065
| New | +$11.8K |
|
1431
Phathom Pharmaceuticals
PHAT
$743M
| $18.6K | ﹤0.01% |
2,279
-191
| -8% | -$2.37K |
|
1432
Annexon
ANNX
$862M
| $18.4K | ﹤0.01% |
+3,552
| New | +$21.9K |
|
1433
Altimmune
ALT
$560M
| $18.2K | ﹤0.01% |
+2,370
| New | +$18.1K |
|
|
CAN
1434
Canaan Creative
CAN
$159M
| $18.2K | ﹤0.01% |
+8,182
| New | +$13.8K |
|
1435
Savara
SVRA
$1.08B
| $18K | ﹤0.01% |
5,719
-234
| -4% | -$816 |
|
|
LX
1436
LexinFintech Holdings
LX
$236M
| $17.7K | ﹤0.01% |
+2,999
| New | +$12.6K |
|
|
TRML
1437
DELISTED
Tourmaline Bio
TRML
| $17.7K | ﹤0.01% |
854
-73
| -8% | -$1.84K |
|
1438
Cartesian Therapeutics
RNAC
$264M
| $17.4K | ﹤0.01% |
4,562
+847
| +23% | +$17.1K |
|
|
ATXS
1439
DELISTED
Astria Therapeutics
ATXS
| $17.2K | ﹤0.01% |
+1,881
| New | +$20K |
|
|
ZK
1440
DELISTED
Zeekr
ZK
| $17.1K | ﹤0.01% |
607
-22
| -3% | -$560 |
|
1441
Xeris Biopharma Holdings
XERS
$1.52B
| $17K | ﹤0.01% |
4,968
-421
| -8% | -$1.35K |
|
|
VERV
1442
DELISTED
Verve Therapeutics
VERV
| $17K | ﹤0.01% |
2,821
-240
| -8% | -$1.35K |
|
1443
Pacific Biosciences
PACB
$357M
| $17K | ﹤0.01% |
9,126
-731
| -7% | -$1.43K |
|
1444
ManpowerGroup
MAN
$2.75B
| $16.9K | ﹤0.01% |
+295
| New | +$18.8K |
|
|
DFTX
1445
Definium Therapeutics
DFTX
$5.9B
| $16.7K | ﹤0.01% |
+2,444
| New | +$16.8K |
|
|
WSR
1446
DELISTED
Whitestone REIT
WSR
| $16.6K | ﹤0.01% |
1,188
-460
| -28% | -$6.56K |
|
1447
CorMedix
CRMD
$639M
| $16.6K | ﹤0.01% |
+2,022
| New | +$20.2K |
|
1448
State Street Blackstone Senior Loan ETF
SRLN
$5.38B
| $16.4K | ﹤0.01% |
394
-30
| -7% | -$1.25K |
|
1449
EyePoint Inc
EYPT
$1.16B
| $16.4K | ﹤0.01% |
2,274
+338
| +17% | +$3.15K |
|
|
TERN
1450
DELISTED
Terns Pharmaceuticals
TERN
| $16.3K | ﹤0.01% |
2,830
+285
| +11% | +$1.93K |
|
Similar funds
BC
Mirae Asset Global Investments's Q4 2024 Portfolio in Review
As of Q4 2024, Mirae Asset Global Investments held 1,702 positions worth $24.6B, up 9% from $22.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Mirae Asset Global Investments deployed $1.28B of net new capital in Q4 2024, opening 151 new positions and adding to 731 existing holdings. Its largest new stake was Strategy Inc: 36,162 shares worth $11.8M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $81.5M trimmed.
- Mirae Asset Global Investments's largest Q4 2024 buy was Strategy Inc: 36,162 shares worth $11.8M.
- Mirae Asset Global Investments added most to Vanguard S&P 500 ETF in Q4 2024, an estimated $167M increase.
- Mirae Asset Global Investments's biggest Q4 2024 reduction was Invesco QQQ Trust, cutting an estimated $81.5M.
- Mirae Asset Global Investments fully exited VanEck Pharmaceutical ETF in Q4 2024, selling an estimated $23.6M.
- Mirae Asset Global Investments's ten largest holdings make up 38% of its $24.6B portfolio in Q4 2024.
- Mirae Asset Global Investments opened 151 new positions and closed 110 in Q4 2024.
- Mirae Asset Global Investments's portfolio value rose 9% quarter-over-quarter to $24.6B.
Based on Mirae Asset Global Investments's 13F filing for Q4 2024, filed 27 Jan 2025.